You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Monitoring immunogenicity of protein-based TNF antagonists

https://doi.org/10.1136/flgastro-2015-100596

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors Conception and drafting of manuscript: KB. Contribution and revision of manuscript, approval of final manuscript: all authors.

    • Competing interests KB has served as a speaker for Pfizer and Biomonitor and owns stocks in Novo-Nordisk and Eurodiagnostica. CS has served as speaker for MSD and Abbvie and as a consultant for MSD, Takeda Pharmaceutical Company Limited and Pfizer. JB has served as advisory board member for Abbvie. OØT has served as a speaker and consultant for UCB and Zealand Pharma and primary investigator for Amgen, Celltrion, Genetech, Novo-Nordisk, Pfizer and Roche.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • ↵i In contrast to Hendy et al, we have no knowledge of laboratories that provide ELISAs that ‘give reliable ADAb levels in the presence of drug’.